Boehringer Ingelheim’s glucagon/GLP-1 dual agonist has driven 16.6% weight loss at Week 76 of a phase 3 study. While the ...

After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...

Novartis is “continuing to evaluate” the in vivo CAR-T space, although the pharma’s CEO has told Fierce Biotech that no deals ...

Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...

Thermo Fisher Scientific is shedding its microbiology business to private equity firm Astorg nearly a year after initial ...

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...

Astellas Pharma has done some spring cleaning of its pipeline, dropping two phase 1 candidates and slamming the brakes on a ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

“Our study highlights the growing potential of advanced biomarker science, combined with machine learning, to detect cancers ...

Both Seaport Therapeutics and Hemab Therapeutics are hoping to bring in around $180 million each from their public listings ...

A simple outpatient procedure currently used for type 2 diabetes patients in Europe can help those on Eli Lilly’s obesity ...